UFPT
UFP Technologies, Inc.217.74
-0.08-0.04%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
1.68BP/E (TTM)
25.32Basic EPS (TTM)
8.60Dividend Yield
0%Recent Filings
8-K
CEO succession planned
UFP Technologies announced CEO R. Jeffrey Bailly's retirement effective June 4, 2026, after the annual meeting, with no disagreements on operations. President Mitchell Rock, a 25-year company veteran, will succeed him as CEO, while Bailly shifts to Executive Chairman for a smooth transition. Rock steps up now.
8-K
Updated MedTech growth targets
UFP Technologies released updated investor presentation materials on December 1, 2025, highlighting ~$600M pro-forma revenue with 92% from MedTech and facilities expansion to Puerto Rico and Maryland. It targets 12-18% revenue growth, 28-31% gross margins, and 17-20% adjusted operating margins over 3-5 years via acquisitions and organic gains in robotic surgery. MedTech sales hit $550M TTM.
8-K
Q3 sales up 6.5%
UFP Technologies posted Q3 sales of $154.6 million, up 6.5% from $145.2 million last year, driven by 7.3% MedTech growth to $142.4 million despite a 2.7% non-medical dip. Net income held flat at $16.4 million ($2.11/share) as $3 million in Illinois labor costs offset gains—absent that, EPS rose 13%. Acquisitions and DR expansions hum. Q4 impact shrinks.
8-K
UFP updates MedTech growth strategy
UFP Technologies released updated investor presentation materials on August 21, 2025, highlighting its transformation into a MedTech-focused CDMO with pro forma annual revenue of ~$600 million and market cap of ~$1.95 billion. The company targets 12-18% revenue growth over three to five years through organic expansion in high-margin segments like robotic surgery and strategic acquisitions, aiming for 28-31% gross margins and 17-20% adjusted operating margins. MedTech now drives 92% of sales, up from $132 million in 2021. Forward-looking statements carry risks from customer concentration and supply chain disruptions.
10-Q
Q2 FY2025 results
UFP Technologies posted solid Q2 FY2025 results, with net sales climbing 37.2% year-over-year to $151.2M, driven by 46.0% medical market growth including $35.7M from recent acquisitions, while organic sales rose 4.9% (derived). Gross margin dipped to 28.8% from 30.0%, hit by $1.2M in AJR integration inefficiencies, yet operating income surged 35.6% to $24.3M and diluted EPS hit $2.21, up 26.3%, reconciling cleanly with 7,773K shares. Year-to-date, sales jumped 39.1% to $299.3M, EPS $4.42 (up 30.8%), and operating cash flow reached $39.1M, yielding $33.5M free cash flow after $5.7M capex (derived). Debt stood at $163.6M under the $275M facility (5.7% rate, compliant), with $14.9M cash; post-quarter buys of UNIPEC ($7.5M cash, July 2025) and TPI ($4.5M cash, July 2025) bolster medical components. Acquisitions fuel momentum. Customer concentration lingers as a risk.
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
MDT
Medtronic plc.
97.72-0.85
MHUA
Meihua International Medical Te
7.61-6.41
NAOV
NanoVibronix, Inc.
4.02-0.29
SNWV
SANUWAVE Health, Inc.
31.46-0.18
STE
STERIS plc (Ireland)
253.03-1.04
UEEC
United Health Products, Inc.
0.06+0.00
UFPI
UFP Industries, Inc.
92.94+0.52
UTMD
Utah Medical Products, Inc.
58.43+0.94